Please login to the form below

Not currently logged in
Email:
Password:

abiraterone

This page shows the latest abiraterone news and features for those working in and with pharma, biotech and healthcare.

J&J’s Erleada cleared for early prostate cancer in Europe

J&J’s Erleada cleared for early prostate cancer in Europe

Xtandi is also approved for more advanced, metastasised CRPC, where it competes with J&J’s $4bn-plus androgen synthesis inhibitor Zytiga (abiraterone acetate), and reported $180m in alliance revenues in

Latest news

More from news
Approximately 5 fully matching, plus 51 partially matching documents found.

Latest Intelligence

  • Deal Watch May 2016 Deal Watch May 2016

    outperforming J&J's Zytiga [abiraterone].

  • Taking a strategic approach Taking a strategic approach

    But in oncology Zytiga (abiraterone) was last year not recommended for an early use indication in final draft guidance from NICE, but that appraisal process is currently on hold after Janssen

  • Pharma deals during October 2013 Pharma deals during October 2013

    AstraZeneca is focusing on developing its regional oncology portfolio as evidenced by the closure of a co-promotion deal with Janssen in Japan for Zytiga (abiraterone acetate), an innovative oral therapy

  • Interview: Cesar Rodriguez, Janssen Interview: Cesar Rodriguez, Janssen

    Janssen is developing its strengths in other areas too, and Rodriguez noted the company's recent developments in oncology, including the launch of abiraterone acetate for prostate cancer – it's “a

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
AMICULUM Limited

AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >220 healthcare communications professionals,...

Latest intelligence

China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...

Infographics